CODE NI
This is an online Blog book to discuss our patients deidentified health data shared after taking his/ her guardians to sign an informed consent
Here we discuss our patient problems through a series of inputs from the available Global online community of experts with n aim to solve those patient clinical problems with the current best evidence-based input
This Blog also reflects my patient-centred online learning portfolio.
Your valuable input on the comment box is welcome
I have been given this case to solve in an attempt to understand the topic of " Patient clinical data analysis" to develop my competence in reading and comprehending clinical data including history, clinical findings, and investigations and coming up with a diagnosis and treatment plan.
DEIDENTIFIED DISCHARGE SUMMARY
PID 202351741
UHID 20231126910
Pay Type
Credit (AROGYA SREE)
Age/Gender 50 Years/Female
Address
Discharge Type: Relieved
Admission Date: 17/11/2023 06:29 PM
Name of Treating Faculty
DR.RAMULU (HOD)
Diagnosis
CKD ON MHD
Case History and Clinical Findings
PATIENT CAME WITH COMPLAINTS OF GENERALISED WEAKNESS SINCE ONE MONTH BILATERAL PEDAL EDEMA INSIDIOUS IN ONSET, GRADUALLY PROGRESSIVE, PITTING TYPE, NO DIURNAL VARIATION SINCE 2 WEEKS AND THEN DEVELOPED SHORTNESS OF BREATH INSIDIOUS IN ONSET, GRADUALLY PROGRESSIVE, GRADE 2, MMRC, NO PND, NO CHEST PAIN
PAST HISTORY
PATIENT IS K/C/O CKD UNDERWENT 3 SESSIONS OF HEMODIALYSIS
K/C/O DM TYPE 2 SINCE 3 YEARS
K/C/O HTN
GENERAL EXAMINATION:
PATIENT IS CONSCIOUS, COHERENT, COOPERATIVE, WELL ORIENTED TO TIME, PLACE AND PERSON
BILATERAL PEDAL EDEMA PRESENT
NO PALLOR, ICTERUS CYANOSIS, CLUBING, LYMPHADENOPATHY
VITALS:
TEMPERATURE:98.5
BP: 140/80 MM HG
PR:78 BPM
RR:18 CPM
SYSTEMIC EXAMINATION:
CVS:S1,S2 HEARD NO MURMURS.
RS BAE + NVES
CNSINO FOCAL NEUROLOGICAL DEFICITS.
Investigation
COMPLETE BLOOD PICTURE (CBP) 17-11-2023 01:06:PMHAEMOGLOBIN9 gm/dITOTAL COUNT9900cells/cummNEUTROPHILS74 %LYMPHOCYTES18 %EOSINOPHILS02 %MONOCYTES06 %BASOPHILS00 % PLATELET COUNT
5.10COMPLETE URINE EXAMINATION (CUE) 17-11-2023 01:06:PMCOLOURPale yellowAPPEARANCEClearREACTIONAcidicSP GRAVITY 1.010ALBUMIN+++SUGAR+BILE
SALTSNIIBILE PIGMENTSNIIPUS CELLS3-4EPITHELIAL CELLS2-4RED BLOOD
CELLSNIICRYSTALSNIICASTSNIIAMORPHOUS DEPOSIT SAbsentOTHERSNILIVER FUNCTION
TEST (LFT) 17-11-2023 01:06:PMTotal Billurubin0.51 mg/dlDirect Bilurubin0.20 mg/dISGOT(AST)11
IU/LSGPT(ALT)10 IU/LALKALINE PHOSPHATE227 IU/LTOTAL PROTEINS7 gm/dIALBUMIN3.41 gm/dIA/G RATIOD.95RFT 17-11-2023 01:06:PMUREA112 mg/dICREATININES mg/dIURIC ACID7.2 mg/dICALCIUM10.1 mg/dIPHOSPHOROUS5.7 mg/dISODIUM 130 mEq/LPOTASSIUM6.1mEq/LCHLORIDE98 mEq/L
2DECHO
TRIVIAL TR PRESENT NO MRIAR
NO RWMA,NO AS/MS, SCLEROTIC AV
EF 67%, GOODLV SYSTOLIC FUNCTION
GRADE 1 DIASTOLIC DYSFUNCTION, NO PAH
USG OF ABDOMEN:
B/L GRADE 2 RPD CHANGES
Treatment Given (Enter only Generic Name)
FLUID RESTRICTION 1.5L/DAY
SALT RESTRICTION <2G/DAY
TAB.SHELCAL PO/OD
TAB OROFER XT PO/OD
TAB LASIX 80 MG PO BO
TAB TELMA 80 MG PO/OD
TAB. NICARDIA 20 MG PO/TID
Advice at Discharge
FLUID RESTRICTION 1.5L/DAY
SALT RESTRICTION-2G/DAY
TAB SHELCAL POIOD
TAB OROFER XT POOD
TAB LASIX 80 MG PO BD
TAB. TELMA 80 MG PO/OD
TAB NICARDIA 20 MG PO/TID
Follow Up
REVIEW TO NEPHRO OPD IN CASE OF SOS
When to Obtain Urgent Care
IN CASE OF ANY EMERGENCY IMMEDIATELY CONTACT YOUR CONSULTANT DOCTOR OR ATTEND EMERGENCY DEPARTMENT.
Preventive Care
AVDID SELF MEDICATION WITHOUT DOCTORS ADVICE, DONOT MISS MEDICATIONS. In case of Emergency or to speak to your treating FACULTY or For Appointments, Please Contact: 08682279999 For Treatment Enquiries Patient/Atendent Declaration: The medicines prescribed and the advice regarding preventive aspects of care, when and how to obtain urgent care have been
explained to me in my own language SIGNATURE OF PATIENT ATTENDER
SIGNATURE OF PG/INTERNEE
SIGNATURE OF ADMINISTRATOR
SIGNATURE OF FACULTY
Discharge Date
Date:25/12/2023
Ward: CKD
Unit NEPHROLOGY
CASE REPORT:
Initial assessment
Hb (gm/dl) 9.1 (NCNC)
BLOOD UREA (mg/dl) 110
Sr.CREATININE (mg/dl) 5.2
eGFR (ml/min/1.72m²) 8.8
Sr.Na+ (mEq/L) 139
Sr.K+ (mEq/L) 6.5
Sr.Cl- (mEq/L) 102
Sr. Ca+2 (mEq/L) 10.0
Sr. Phosphorus (mEq/L) 5.7
TOTAL BILIRUBIN (mg/dl) 0.51
DIRECT BILIRUBIN (mg/dl) 0.20
AST/SGOT (IU/L) 11
ALT/SGPT (IU/L) 10
ALP (IU/L) 227
TOTAL PROTEINS (gm/dl) 7.0
Sr.ALBUMIN (gm/dl) 3.41
CUE Albumin+3, Sugars +1
Sr. Fe (mcg/dl) 70
Usg
RIGHT kidney 7.5 x 3.1cms, CMD PARTIALLY MAINTAINED
LEFT kidney 7.7 x 4.4 cms, CMD PARTIALLY MAINTAINED
IMPRESSION
BILATERAL GRADE 2-3 RPD CHANGES
2D ECHO -
EF 67%
Mild LVH
No Dilated chambers
Good LV systolic function
Grade 1 LV diastolic dysfunction
No RWMA
Minimal Pericardial effusion
Trivial TR
Follow up assessment
Hb (gm/dl) 8.3 (NCNC)
BLOOD UREA (mg/dl) 86
Sr.CREATININE (mg/dl) 8.7
eGFR (ml/min/1.72m²) 4.8
Sr.Na+ (mEq/L) 144
Sr.K+ (mEq/L) 3.5
Sr.Cl- (mEq/L) 106
Sr. Ca+2 (mEq/L) 9.7
Sr. Phosphorus (mEq/L) 4.7
TOTAL BILIRUBIN (mg/dl) 0.48
DIRECT BILIRUBIN (mg/dl) 0.20
AST/SGOT (IU/L) 11
ALT/SGPT (IU/L) 10
ALP (IU/L) 270
TOTAL PROTEINS (gm/dl) 5.50
Sr.ALBUMIN (gm/dl) 2.91
CUE Albumin +3, Sugars Nil
Sr. Fe (mcg/dl) 56
2D ECHO -
EF 66%
Mild LVH
No Dilated chambers
Good LV systolic function
Grade 1 LV diastolic dysfunction
No RWMA
Minimal Pericardial effusion
Mild TR, Trivial TR
HFA-PEFF DIAGNOSTIC ALGORITHM FOR DIAGNOSIS OF HFpEF :
Major criteria:
1. Functional
septal e’<7 cm/s or lateral e' < 10 cm/s or Average E/e'≥ 15 or TR velocity > 2.8 m/s (PASP>35 mmHg)
2. Morphological
LAVI > 34 ml/m² or LVMI >=149/122 g/m² (m/w) and RWT>0,42 #
3. Biomarker (SR)
NT-proBNP > 220 pg/ml or BNP > 80 pg/ml
4. Biomarkers (AF)
NT-proBNP > 660 pg/ml or BNP >240 pg/ml
Minor criteria:
1. Functional
Average E/e' 9-14 or GLS<16%
2. Morphological
LAVI 29-34 ml/m² or LVMI>115/95 g/m² (m/w) or RWT > 0,42 or LV wall thickness≥12 mm
3. Biomarker (SR)
NT-proBNP 125-220 pg/ml or BNP 35-80 pg/ml
4. Biomarkers (AF)
NT-proBNP 365-660 pg/ml or BNP 105-240 pg/ml
Each Major Criteria: 2 points
Each Minor Criteria: 1 point
≥ 5 points: HFpEF
2-4 points: Diastolic Stress Test or Invasive Haemodynamic Measurements
Criteria for HFpEF Diagnosis
Major Criteria:
Functional:
Septal e’ < 7 cm/s or lateral e' < 10 cm/s or Average E/e' ≥ 15 or TR velocity > 2.8 m/s (PASP > 35 mmHg)
Follow-up PASP: 35 mmHg (meets major criteria 2 points)
Morphological:
LAVI > 34 ml/m² or LVMI ≥ 122 g/m² (women) and RWT > 0.42
RWT: Increased in both assessments (meets major criteria 2 points)
Minor Criteria:
Functional:
Average E/e' 9-14 or GLS < 16% (grade I DD)
Morphological:
LAVI 29-34 ml/m² or LVMI > 95 g/m² (women) or RWT > 0.42 or LV wall thickness ≥ 12 mm
RWT and LV Wall Thickness: Increased and ≥ 12 mm (meets minor criteria 1 point)
Conclusion:
Initial echo:
Major Criteria: 2 point for Morphological
Minor Criteria: 1 point for RWT and LV wall thickness.
3 points need further testing
Follow up echo:
Major Criteria: 2 point each for Functional and morphological criteria
Minor Criteria: 1 point for RWT and LV wall thickness.
5 points
HFpEF.
Comments
Post a Comment